NCT02444234View on ClinicalTrials.gov

Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis

PHASE4CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Cystic Fibrosis
Interventions
DRUG

Tedizolid PO

Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.

DRUG

Tedizolid IV

Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.

Trial Locations (1)

90089

University of Southern California, Los Angeles

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Southern California

OTHER

NCT02444234 - Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis | Biotech Hunter | Biotech Hunter